Switch to Standard View
MyBreastCancerTreatment.org

Helping Guide Your Early-Stage Breast Cancer Treatment Decisions.

866.941.1214
Get Updates
Gail - Breast Cancer Patient
Every breast cancer tumor is different.
Gail - Breast Cancer Patient
Laurie - Breast Cancer Patient
The genes in your tumor can
help individualize your treatment.
Laurie - Breast Cancer Patient
Coree - Breast Cancer Patient
The Oncotype DX® genomic test
helps you assess your treatment options.
Coree - Breast Cancer Patient
Angela - Breast Cancer Patient Angela - Breast Cancer Patient
Oncotype DX is a genomic test that may help guide
treatment decisions for patients with DCIS or ER+
early-stage invasive breast cancer.
Angela - Breast Cancer Patient
Arrow About Oncotype DX
Arrow Eligibility Quiz

Is the Oncotype DX® breast cancer test right for you?

Take Eligibility Quiz

Questions to ask
your doctor

Get a discussion guide for the Oncotype DX breast cancer test.

View Discussion Guide

...About Oncotype DX

and Personalized Treatment

for Breast Cancer

Watch the Video

DCIS Test Available

Learn about a new test for
patients with ductal carcinoma
in situ (DCIS), or pre-invasive breast cancer

Learn More

Ductal Carcinoma in situ (DCIS), or Estrogen Receptor Positive (ER+)

The information presented on this site is intended to provide patients with newly diagnosed invasive or pre-invasive breast cancer (medically known as Ductal Carcinoma In Situ), as well as their friends and family, an opportunity to hear how others have incorporated the information provided by the Oncotype DX® Recurrence Score® in making treatment decisions with their doctors. The personal stories featured on this site selected by Genomic Health, Inc., which offers the Oncotype DX® tests, are not intended to be representative of patients with breast cancer generally, and should not be considered medical advice. Patients should consult their doctor to determine the best treatment decision for their individual disease.

American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy.

Copyright © 2004-2012 Genomic Health, Inc. All rights reserved. Genomic Health, Oncotype, Oncotype DX, Recurrence Score, and Pass It On: Until Every Woman Knows are trademarks of Genomic Health Inc. MyBreastCancerTreatment.org is sponsored by Genomic Health, Inc., a clinical laboratory in Redwood City, California that developed and offers the Oncotype DX® Breast Cancer Assay. Genomic Health is responsible for the content of MyBreastCancerTreatment.org.